Highlights
- EPS (TTM)
- $0.46
- PE Ratio
- 104.54
- PEG Ratio
- 1.01
- Total Revenue (TTM)
- $597.97M
- Gross Profit (TTM)
- $315.52M
- EBITDA (TTM)
- $45.10M
- Year Range
- $18.26 - $49.12
- Target Price
- $55.67
- ROA (TTM)
- 4.70%
- ROE (TTM)
- 6.33%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Kiniksa Pharmaceuticals, Ltd., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Kiniksa Pharmaceuticals, Ltd. (KNSA) has returned 16.73% so far this year and 116.79% over the past 12 months.
Kiniksa Pharmaceuticals, Ltd.
- 1D
- 5.36%
- 1M
- 8.23%
- YTD
- 16.73%
- 6M
- 24.00%
- 1Y
- 116.79%
- 3Y*
- 64.79%
- 5Y*
- 21.11%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since May 24, 2018, KNSA's average daily return is +0.12%, while the average monthly return is +2.32%. At this rate, your investment would double in approximately 2.5 years.
Historically, 54% of months were positive and 46% were negative. The best month was Aug 2018 with a return of +57.5%, while the worst month was Jan 2019 at -37.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.
On a daily basis, KNSA closed higher 50% of trading days. The best single day was Jul 25, 2023 with a return of +30.4%, while the worst single day was Mar 16, 2020 at -24.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.47% | 1.30% | 8.23% | 16.73% | |||||||||
| 2025 | -0.91% | 3.47% | 9.52% | 21.43% | 1.45% | 1.13% | 9.36% | 10.67% | 15.95% | -4.69% | 14.89% | -2.99% | 108.54% |
| 2024 | 0.51% | 19.91% | -6.67% | -5.12% | 1.55% | -1.79% | 42.47% | 0.53% | -6.54% | -9.60% | -2.26% | -10.42% | 12.77% |
| 2023 | -3.47% | -11.07% | -16.33% | -0.09% | 28.93% | 1.59% | 33.81% | -8.55% | 0.81% | -12.20% | 6.03% | 8.47% | 17.09% |
| 2022 | -4.59% | -8.82% | -2.93% | -6.14% | -17.90% | 26.50% | 2.27% | 18.26% | 9.56% | -11.06% | 47.37% | -10.99% | 27.27% |
| 2021 | 11.43% | 4.47% | -10.01% | -11.08% | -17.19% | 2.20% | 10.05% | -17.94% | -9.46% | -8.78% | 11.84% | 1.29% | -33.39% |
Benchmark Metrics
Kiniksa Pharmaceuticals, Ltd. has an annualized alpha of 21.17%, beta of 0.93, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since May 25, 2018.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (36.70%) than losses (5.46%) — typical of diversified or defensive assets.
- R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 21.17%
- Beta
- 0.93
- R²
- 0.08
- Upside Capture
- 36.70%
- Downside Capture
- 5.46%
Return for Risk
Risk / Return Rank
KNSA ranks 95 for risk / return — in the top 95% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and compare them to a chosen benchmark (S&P 500 Index).
| KNSA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.68 | 0.90 | +1.79 |
Sortino ratioReturn per unit of downside risk | 3.46 | 1.39 | +2.07 |
Omega ratioGain probability vs. loss probability | 1.44 | 1.21 | +0.23 |
Calmar ratioReturn relative to maximum drawdown | 6.77 | 1.40 | +5.37 |
Martin ratioReturn relative to average drawdown | 22.32 | 6.61 | +15.71 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore KNSA risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kiniksa Pharmaceuticals, Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kiniksa Pharmaceuticals, Ltd. was 83.06%, occurring on Oct 18, 2019. Recovery took 1453 trading sessions.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -83.06% | Sep 21, 2018 | 271 | Oct 18, 2019 | 1453 | Aug 1, 2025 | 1724 |
| -34.99% | Jun 21, 2018 | 26 | Jul 27, 2018 | 23 | Aug 29, 2018 | 49 |
| -13.47% | Sep 11, 2018 | 3 | Sep 13, 2018 | 4 | Sep 19, 2018 | 7 |
| -12.87% | Dec 23, 2025 | 16 | Jan 15, 2026 | 7 | Jan 27, 2026 | 23 |
| -12.12% | May 25, 2018 | 4 | May 31, 2018 | 14 | Jun 20, 2018 | 18 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kiniksa Pharmaceuticals, Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kiniksa Pharmaceuticals, Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for KNSA, comparing it with other companies in the Biotechnology industry. Currently, KNSA has a P/E ratio of 104.5. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for KNSA compared to other companies in the Biotechnology industry. KNSA currently has a PEG ratio of 1.0. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KNSA relative to other companies in the Biotechnology industry. Currently, KNSA has a P/S ratio of 6.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |